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Compared with other cancers, diabetes mellitus is more closely associated with hepatocellular carcinoma
(HCC). However, whether hyperglycemia is associated with hepatic carcinogenesis remains uncertain. In
this study, we investigate the effect of hyperglycemia on HCC development. Mice pretreated with 7,12-
dimethylbenz (a) anthracene were divided into three feeding groups: normal diet (Control), high-starch
diet (Starch), and high-fat diet (HFD) groups. In addition, an STZ group containing mice that were fed a
normal diet and injected with streptozotosin to induce hyperglycemia was included. The STZ group
demonstrated severe hyperglycemia, whereas the Starch group demonstrated mild hyperglycemia and
insulin resistance. The HFD group demonstrated mild hyperglycemia and severe insulin resistance.
Multiple HCC were macroscopically and histologically observed only in the HFD group. Hepatic steatosis
was observed in the Starch and HFD groups, but levels of inﬂammatory cytokines, interleukin (IL)-6,
tumor necrosis factor-a, and IL-1b, were elevated only in the HFD group. The composition of gut
microbiota was similar between the Control and STZ groups. A signiﬁcantly higher number of Clos-
tridium cluster XI was detected in the feces of the HFD group than that of all other groups; it was not
detectable in the Starch group. These data suggested that hyperglycemia had no effect on hepatic
carcinogenesis. Different incidences of HCC between the Starch and HFD groups may be attributable to
degree of insulin resistance, but diet-induced changes in gut microbiota including Clostridium cluster XI
may have inﬂuenced hepatic carcinogenesis. In conclusion, in addition to the normalization of blood
glucose levels, diabetics may need to control insulin resistance and diet contents to prevent HCC
development.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Epidemiological studies have shown that the incidence of
various cancers, including cancers of the bladder, breast, colon,
endometrium, liver, and pancreas, are signiﬁcantly elevated inthracene; SASP, senescence-
D, normal diet.
ology and Diabetes, Nagoya
-cho, Showa-ku, Nagoya 466-
sunekawa).
r Inc. This is an open access articlpatients with diabetes mellitus (DM) [1,2]. The relative risk of
hepatocellular carcinoma (HCC) is the most closely associated
with DM [3,4].
The incidence and mortality of HCC ranks the ﬁfth highest in
that of all cancers [5]. Important etiological risk factors of HCC
include hepatitis viral inﬂammation, nonalcoholic steatohepatitis,
obesity, and smoking. DM is also considered to be associated with
a 2.5-fold increased risk for HCC [6,7]. Chronic inﬂammation, in-
sulin resistance with hyperinsulinemia, and changes in gut micro-
biota are reported to be associated with carcinogenesis in the
livers of DM patients [8e11]. Systemic and local inﬂammation oc-
curs in obese DM patients [12]. Inﬂammatory changes in the livere under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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cellular proliferation, angiogenesis, and apoptosis suppression,
resulting in HCC development [8,13]. Hyperinsulinemia associated
with insulin resistance in DM patients promotes protein synthesis,
cellular proliferation, and apoptosis suppression, resulting in ac-
celeration of tumor progression [9]. A recent study also reported
that gut microbiota, particularly Clostridium cluster XI, play an
important role in HCC development through senescence-associated
secretory phenotype (SASP) of hepatic stellate cells in high-fat diet
(HFD) fed mice [14].
Hyperglycemia is suggested to increase the risk of developing
cancer [15]. Hyperglycemia in patients with type 2 DM increases
the breast cancer-associated mortality risk [16]. Oxidative stress,
hypoxia-inducible factor-1a (HIF-1a), and epigenetic changes
induced by hyperglycemia promote tumor progression in pancre-
atic and breast cancer cell lines [17]. Hyperglycemia can increase
the level of serum inﬂammatory cytokines [18]. These studies
suggest that hyperglycemia can potentially promote HCC
development.
However, it remains uncertain whether hyperglycemia alone,
without any concomitant factors, is associated with carcinogenesis
in the liver of DM patients. In this study, we investigate the effect
of hyperglycemia on HCC development.
2. Materials and methods
2.1. Animal model
C57Bl/6J mice (Chubu Kagaku Shizai Co. Ltd., Japan), were
housed in a temperature-controlled room under conditions of the
12 h light/dark cycle, with free access to food and water. All pro-
cedures were performed according to a protocol approved by the
Nagoya University Institutional Animal Care and Use Committee.
Carcinogenesis was initiated in male mice using 7,12-dimethylbenz
(a) anthracene (DMBA; Sigma). Treatment comprised a single
application of 50 mL of 0.5% DMBA solution in acetone to the dorsal
surface on postnatal day 4. Next, the mother mice and the pups
were fed with a normal diet. At 4 weeks old, pups wereweaned and
subsequently fed with a normal diet, high-starch diet (Starch) or
HFD, until euthanization at 40 weeks after DMBA administration.
Control groups were fed on a normal diet (ND; CLEA Japan, Osaka,
Japan) containing 4.2% fats and 54.6% carbohydrates. A streptozo-
tosin (STZ; SigmaeAldrich) group was fed with the ND and intra-
peritoneally (i.p.) injected with STZ. STZ was dissolved in saline and
injected at 50 mg/kg body weight daily for 5 days starting at the
ninth week of age. This injection helped induce the pancreatic
damage causing DM. Starch groups were fed with Starch (CLEA
Japan, Osaka, Japan) containing 12.8% fats and 74.1% carbohydrates.
HFD groupwas fed with HFD (HFD32; Chubu Kagaku Shizai Co. Ltd.,
Japan) containing 32% fats and 29.4% carbohydrates.
2.2. Random blood glucose levels and body weight
Random blood glucose levels and body weight were measured
day at 09:00. Blood glucose levels were measured with Antsense III
(Horiba, Kyoto, Japan).
2.3. Intraperitoneal glucose tolerance test (IPGTT)
IPGTT was conducted at 32 weeks. After 16 h of fasting,
D-glucose, 2 g/kg body weight, was injected i.p. into the treated
mice. Plasma glucose levels were then measured at 0, 15, 30, 60,
and 120 min after the injection. Plasma insulin levels were
measured using a mouse insulin enzyme-linked immunosorbent
assay kit (Morinaga, Tokyo, Japan) at the same time points.2.4. Insulin tolerance test (ITT)
ITT was conducted at 32 weeks. After 6 h of fasting, regular in-
sulin (Humulin U-100; Lilly, Indianapolis, IN), 0.6 g/kg body weight,
was injected i.p. into the treated mice. Plasma glucose levels were
then measured at 0, 15, 30, 60, and 120 min after the injections.
2.5. Area under the curve (AUC)
AUC for glucose (mg min/dL) and insulin (ng min/mL) was
calculated, as described previously [19].
2.6. Triglyceride measurement
The liver tissue was isolated at 40 weeks after DMBA adminis-
tration and then homogenized with isopropyl alcohol (Wako,
Tokyo, Japan). The triglyceride content in the liver tissue was
measured using the Triglyceride E-test kit (Wako, Tokyo, Japan).
2.7. Histological analyses
The liver was ﬁxed in 4% paraformaldehyde, sequentially
washed thoroughly in PBS, and embedded in parafﬁn wax. The
specimens were sectioned at a thickness of 4 mm and stained with
hematoxylineeosin staining. Steatosis in the liver was assessed by
the steatosis score, as described by Kleiner et al. [20], with separate
scores for steatosis (0e3). Liver ﬁbrosis was assessed using Sirius
red staining, and the areas with positive Sirius red staining were
measured using a BZ-9000 ﬂuorescent microscope system (Key-
ence, Osaka, Japan) in ﬁve microscopic ﬁelds at a 200-fold magni-
ﬁcation. All liver specimens were assessed by two hepatologists
blinded to the identities of the study groups.
2.8. RNA expression of cytokine
Total RNA was extracted from each liver and HCC using the
RNeasy® Plus Mini kit from Qiagen (Valencia, CA, USA). RNA
expression of interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a),
and IL-1b relative to GAPDH was quantiﬁed using Power SYBR
Green RNA-to-CTTM 1-Step kit in a 7300 Real-Time PCR system
(Applied Biosystems, Foster City, CA, USA). The following primer
sets were used: For IL-6, forward primer: 50-CCGGAGAGGAGACTTC
ACAG-30 and reverse primer: 50-TCCACGATTTCCCAGAGAAC-30. For
TNF-a, forward primer: 50-TATGGCTCAGGGTCCAACTC-30 and
reverse primer: 50-CTCCCTTTGCAGAACTCAGG-30. For IL-1b, for-
ward primer: 50-GATCCACACTCTCCAGCTGCA-30 and reverse
primer: 50-CAACCAACAAGTGATATTCT-30. For GAPDH, forward
primer: 50-CCAATGTGTCCGTCGTGGAT-30 and reverse primer: 50-
TGCTGTTGAAGTCGCAGGAG-30.
2.9. Bacterial 16S rRNA ampliﬁcation sequencing and analysis
Fecal samples were collected frommice at 40 weeks after DMBA
administration. DNA was extracted from the feces and the large
intestinal microbiota was analyzed using terminal restriction
fragment length polymorphisms (T-RFLP), as described previously
[21e23].
2.10. Determination of the copy number of fecal bacteria
The copy number of Clostridium cluster XI was calculated from
the standard curve of known bacterial copy number by quantitative
real-time PCR of 16S rRNA gene using 50-TGACGGTACYYNRKGAGG
AAGCC-30 and 50-ACTACGGTTRAGCCGTAGCCTTT-30 primers as
described previously [24].
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Data is expressed as the mean ± standard error. Comparisons
among quantitative variable groups were performed using analysis
of variance with the Tukey post-hoc test via Graph Pad Prism
(v.6.03; Graph Pad Software, San Diego, CA, USA). P-value  0.05
was considered statistically signiﬁcant.
3. Results
3.1. Incidence of hepatocellular carcinoma
We examined the effect of glucose intolerance on HCC devel-
opment in the STZ, Starch, or HFD group mice in comparison with
the Control group mice. All the mice were pretreated with DMBA
on the postnatal day 4.
Multiple HCC were macroscopically observed only in the HFD
group (Fig. 1A). The incidence of HCC was 100% in the HFD group
(Fig. 1B). The HFD group showed a signiﬁcant increase in liver
weight compared with the other groups (Fig. 1C).
3.2. Glucose intolerance and insulin resistance
The STZ, Starch, and HFD groups showed signiﬁcantly greater
mean random blood glucose levels than the Control group for the
30-week period. The random blood glucose levels in the STZ group
were signiﬁcantly greater than those in the other groups (Fig. 2A).
The mean body weight of both the Starch and HFD groups was
signiﬁcantly greater than and that of STZ group was signiﬁcantly
lower than the Control group over the 30-week period (Fig. 2B).
IPGTT study at 32 weeks showed that the plasma glucose levels
were signiﬁcantly higher in STZ, Starch, and HFD groups than in
the Control group. The glucose AUC during IPGTT in STZ group was
the highest among all groups as shown in Fig. 2C [Glucose AUCFig. 1. Incidence of HCC. (A) The livers of mice in the Control, STZ, Starch, and HFD group
(B) Liver weights of each group at 40 weeks after the administration. (C) Tumor incidence
error (n ¼ 6). zP < 0.05, vs. HFD.(mg min/dl): 33,870 ± 2162.8 (Control), 55,612 ± 4381.9 (STZ),
43,029 ± 3317.4 (Starch) and 39,863 ± 4397 (HFD)]. The plasma
insulin levels during IPGTT were signiﬁcantly higher in the Starch
and HFD groups and lower in the STZ group than in the Control
group. The insulin AUC in the HFD group was signiﬁcantly higher
than that in the other groups as shown in Fig. 2D [Insulin AUC
(ng min/ml): 29,313 ± 4780.5 (Control), 9834.8 ± 5396.1 (STZ),
42,050 ± 16,354 (Starch) and 1,25,898 ± 13,547 (HFD)]. ITT at 32
weeks showed insulin resistance in the HFD and Starch groups but
not in the STZ or Control group (Fig. 2E). The insulin resistance in
the HFD group was more remarkable than that in the Starch group
[percentages of blood glucose at 60 min after insulin injection:
30.6% ± 2% (Control), 34.8% ± 1% (STZ), 55.1% ± 3% (Starch), and
71.8% ± 4% (HFD)]. These data suggest that hyperglycemia rarely
inﬂuences HCC development; nevertheless, insulin resistance may
be associated with HCC development.3.3. Histopathological observations in the liver and HCC
Histopathological analysis showed that the HCC development
was observed only in the HFD group with hematoxylineeosin
staining and were not observed in the other groups at 40 weeks
after DMBA administration (Fig. 3A). The tissue sections prepared
from the HFD group showed the development of HCC with distinct
nuclear atypia and pleomorphism (Fig. 3B), which is in a clear
contrast to non-HCC area, as described previously [11]. Macroscopic
and histopathological observations indicated hepatic steatosis in
the Starch and HFD groups (Fig. 3A). The steatosis score was
signiﬁcantly increased in the Starch and HFD groups but not in the
STZ or Control group (Fig. 3C). The score in the HFD group was
signiﬁcantly higher than that in the Starch group. The liver tri-
glyceride content was signiﬁcantly increased in the Starch and
HFD groups compared with that in the Control and STZ groups
(Fig 3D). The hepatic triglyceride content in the HFD group wass at 40 weeks after administration of 50 mL 0.5% solution of DMBA at 4 days of age.
in the livers of each group at 40 weeks. The data are expressed as mean ± standard
Fig. 2. Glucose tolerance and insulin resistance. (A) Random blood glucose levels and (B) body weights of each mouse of all groups were measured for 30 weeks. (C) Plasma
glucose levels and (D) insulin plasma levels of each mouse of all groups during IPGTT were measured at 32 weeks after DMBA administration. (E) Percentages of glucose change
in each group were measured by ITT at 32 weeks after DMBA administration. Data are expressed as mean ± standard error (n ¼ 6). *P < 0.05, vs. Control. yP < 0.05, vs. Starch.
zP < 0.05, vs. HFD.
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demonstrated that the percentage of Sirius red-positive areas in
the HFD groupwas signiﬁcantly higher than that in all other groups
(Fig. 3E). The hepatic ﬁbrosis in the HFD group was denoted as light
hepatic ﬁbrosis. These results suggest that the degree of hepatic
steatosis may be associated with HCC development.3.4. Inﬂammatory cytokine expression in the liver and change in
gut microbiota
Furthermore, we examined inﬂammatory state of the liver.
mRNA expression levels of inﬂammatory cytokines including IL-6,
TNF-a, and IL-1b in the liver at 40 weeks after DMBA administra-
tion were signiﬁcantly higher in the HFD group than in the other
groups. mRNA expression levels of these inﬂammatory cytokines in
tumor tissues were signiﬁcantly higher than in normal tissues of
the HFD groupmice (Fig 4A, B, C). The Starch group showed hepatic
steatosis but not inﬂammatory cytokine level elevation or tumori-
genesis. These differences between the Starch and HFD groups may
be associated with not only insulin resistance but also other factors,
such as gut microbiota.
The examination of gut microbiota by the T-RFLP at 40 weeks
after DMBA administration showed that the composition of gut
microbiota in the STZ group was similar to that of the Control
group. The composition of gut microbiota in the HFD group was
signiﬁcantly different from that in the Control group, and the
proportion of fecal Lactobacillus were remarkably lower in the HFD
group than in the other groups (Fig. 4D). The T-RFLP analyses and
quantitative real-time PCR of 16S rRNA gene demonstrated that
the number of Clostridium cluster XI had markedly increased in
HFD group compared with the other groups. Notably, Clostridium
cluster XI were completely undetectable in the Starch group
(Fig. 4D, E). This data suggest that alterations in gut microbiota,
such as an increase in the number of Clostridium cluster XI in HFD,
may play important role in HCC development.4. Discussion
In this study, both the STZ group mice (with severe hypergly-
cemia) and Starch group mice (with moderate hyperglycemia and
hyperinsulinemia) did not show HCC development. Conversely,
HCC was observed only in the HFD group mice (with moderate
hyperglycemia and severe hyperinsulinemia). These data suggest
that hyperglycemia has no effect on HCC development. The differ-
ences between the Starch and HFD groups indicate that the degree
of insulin resistance and the diet-induced change in gut microbiota
may inﬂuence HCC development.
Hyperglycemia is reported to promote some carcinogenesis
types. HeLa cells transplanted into hyperglycemic nude mice
showed an increase in cell proliferation through up-regulation of
HIF-1a expression and of vascular endothelial growth factor tran-
scription [25]. Epigenetic modiﬁcation by hyperglycemia is also
reported to accelerate carcinogenesis in breast cancer [26]. How-
ever, in this study, hyperglycemia without other concomitant fac-
tors did not promote HCC development. Another study reported
that hyperglycemia induced by STZ suppressed breast cancer
development in DMBA-treated mice [27]. No epidemiological
study has shown that the incidence of HCC is elevated in patients
with type 1 DM. It remains controversial whether hyperglycemia
in patients with type 1 DM signiﬁcantly promotes other carcino-
genesis types [15,28]. These studies suggest that hyperglycemia
without other concomitant factors may not affect HCC
development.
It is well known that hyperinsulinemia and chronic inﬂamma-
tion in liver is associated with hepatic carcinogenesis [29,30].
Enhanced insulin and insulin-like growth factor 1 signaling pro-
motes protein translation, cell proliferation, and apoptosis sup-
pression through RASemitogen-activated protein kinase (MAPK)
and phosphoinositide-3-kinaseeAKT pathways, resulting in the
promotion of cancer cell growth [30]. Insulin receptor substrate-1-
knockout mice fed with HFD were protected against liver tumori-
genesis [31]. Therefore, HCC may not develop in the STZ group due
Fig. 3. Histopathological observations in the liver and HCC. (A) Representative histological observations of different experimental mice livers at 40 weeks (hematoxylineeosin
staining; 200 magniﬁcation) (B) Representative hematoxylineeosin-stained images of sections from non-tumor and tumor regions developed in the HFD-fed mice. The box areas
in the left panel are magniﬁed (400) in right panels. (C) Liver steatosis was observed by hematoxylineeosin staining in each group. The steatosis was designated as the steatosis
score. (D) Liver triglycerides in each mouse were determined by a colorimetric assay at 40 weeks after DMBA administration. (E) Liver ﬁbrosis was observed by Sirius red staining
in each group. The extent of liver ﬁbrosis was quantiﬁed as the percentage of Sirius red-positive areas in each group. The data are expressed as mean ± standard error (n ¼ 3).
*P < 0.05, vs. Control. yP < 0.05, vs. Starch.
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hyperglycemia and hyperinsulinemia did not have HCC. High
levels of inﬂammatory cytokines including IL-6, TNF-a, and IL-1b
enhances various signaling pathways. These pathways includes
Janus kinase/Signal transducer activator of transcription 3 pathway
and extracellular signal-regulated kinases pathway; it also
activates IKKa/nuclear factor-kappa B pathway, resulting in the
suppression of apoptosis and cell proliferation in hepatocytes
[32e34]. In this study, hepatic inﬂammation was not observed in
the hyperglycemic STZ and Starch groups, although hyperglycemia
reportedly induces inﬂammation in other tissues such as themicro-
andmacrovasculature through reactive oxygen species or advanced
glycation end product level elevation or epigenetic changes [35].
Steatosis is the most common cause of hepatic inﬂammation [29].
Insulin signaling suppresses lipolysis and promotes lipogenesis in
the liver [30]; the STZ group with hypoinsulinemia did not show
hepatic steatosis and did not demonstrate liver inﬂammation or
tumorigenesis. However, the Starch group with hepatic steatosisdid not demonstrate increase in inﬂammatory cytokines or
tumorigenesis. The difference between the Starch and HFD groups
may be attributable to the degree of insulin resistance and level
of plasma insulin, but other factors might have inﬂuenced hepatic
carcinogenesis as well.
A recent study has shown that gut microbiota is involved in
HCC development. Clostridium cluster XI, of which the number
increased in the HFD group mice, produces the dichloroacetate and
plays an important role in HCC development through SASP of he-
patic stellate cells [11]. Composition of gut microbiota in the STZ
group was highly similar to that of the Control group, suggesting
that hyperglycemia without other concomitant factors did not
change the proportion of gut microbiota. Clostridium cluster XI in
the feces was not detected in the Starch group, which may have
contributed to the different incidences of HCC between the HFD
and Starch groups, although both groups had hyperglycemia,
hyperinsulinemia, and hepatic steatosis. Furthermore, the propor-
tion of fecal Lactobacillus, which were reported to decrease in
Fig. 4. Inﬂammatory cytokine expression in the liver and intestinal microbiota (A, B, C) The mRNA expression levels of IL-6, TNF-a, and IL-1b in the tissue of normal livers in each
group and the tissue of HCC in the HFD group were determined by quantitative real-time PCR at 40 weeks after the administration of DMBA. (D) The proportion of fecal bacteria of
each group were measured by T-RFLP at 40 weeks after DMBA administration. (E) Number of Clostridium cluster XI in feces (1 g) of each group were determined by quantitative
real-time PCR at 40 weeks after DMBA administration. Data are expressed as mean ± standard error (n ¼ 3). yP < 0.05, vs. Starch. zP < 0.05, vs. HFD.
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lower in the HFD group [36]. These combined results suggest that
the diet-induced changes in gut microbiota may inﬂuence HCC
development.
In conclusion, our results suggest that hyperglycemia without
any concomitant factors cannot increase the risk of HCC develop-
ment. The degree of insulin resistance, hepatic steatosis, inﬂam-
mation in the liver, and particularly, diet-induced changes in gut
microbiota may inﬂuence HCC development. In addition to the
normalization of blood glucose levels, DM patients may need to
control insulin resistance and diet contents to prevent HCC
development.
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